Kinloch Capital’s Abiomed Inc ABMD Stock Holding History

Kinloch Capital’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-300	Closed	-$97K	–	228
2020 Q4	$97K	Buy	+300	New	+$83K	0.08%	71

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Kinloch Capital's ABMD Position: Q1 2021 in Review

Kinloch Capital sold out of Abiomed Inc (ABMD) in Q1 2021, closing a stake of 300 shares — an estimated $97K sold.

Kinloch Capital first reported a position in ABMD in Q4 2020 and held it in 1 quarter. The position peaked at $97K in Q4 2020. 487 funds tracked by Wall St. Rank hold ABMD as of Q1 2021.

Kinloch Capital reported no remaining Abiomed Inc position as of Q1 2021 after selling out during the quarter.
Kinloch Capital sold 300 Abiomed Inc shares in Q1 2021, an estimated $97K.
Kinloch Capital first reported a position in Abiomed Inc in Q4 2020 and held it in 1 quarter.
Kinloch Capital's Abiomed Inc position peaked at $97K in Q4 2020.
487 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2021.

Based on Kinloch Capital's 13F filing for Q1 2021, filed 11 May 2021.